Magnesium and Cognition After Stroke

BDH-Klinik Hessisch Oldendorf

Status: Enrolling

Conditions: Stroke; Cognition; Neurologic Disorder; Magnesium

Treatments: Diagnostic Test: Kölner Neuropsychologische Screening für Schlaganfall-Patienten

Study type: Observational

Funder types: Other

Identifiers

NCT05132517

MaSeKo

Details and patient eligibility

About

Cognitive impairments such as memory impairments, word-finding difficulties, compromised orientation and perception are often observed in stroke patients.

Low serum-mg-concentrations are associated with cognitive impairments in ischemic stroke patients one month after stroke onset. It is not clear, if cognitive impairments after stroke is caused by the mg-deficiency or by the stroke itself. Until now, no studies investigating the relationship between mg-concentration, stroke severity and cognition during treatment course are available. Thus, this study aimed to investigate the relationship between mg-concentration and cognition of stroke patients.

Full description

Stroke patients admitted to the stroke unit will be included. Initial mg-concentration in serum as well as stroke related measures (National Institutes of Health Stroke Scale, Scandinavian Stroke Scale, modified Rankin Scale) will be ealuated. Moreover, the cognitive abilities of the patient will be assessed within the first three days via the Kölner Neuropsychologische Screening for stroke patients as well as the Mini Mental Status Test.

During stroke rehabilitation mg-level, stroke related measures (NIHSS,SSS,MRS) as well as the cognitive tests (MMST,KöpSS) will be re-assed after 4 weeks, 3 month as well as at study end, which is defined as discharge from the clinic (death, transfer to another hospital without return after 4 weeks, discharge to long-term nursing/ home/hospice).

Attention-network of stroke patients are measeared if the patient undergo a MRi scan.

In this study following questions will be assessed:

1. What is the incidence of cognitive impairments in stroke patients?

   1. Are there differences between ischemic and hemorrhagic stroke patients?
   2. Are there age and/or gender differences?

2. Are there differences regarding the mg-concentration at admission in comparison to the follow-up (week 4 after admission, 3 month after admission) and between patients with/without cognitive impairments?

3. Is there a correlation between the mg-concentration and the stroke severity?

4. Is there a correlation between the scores of the different cognitive tests (MMST and KöpSS)?

5. Is there an association between the stroke severity, the cognitive impairments (KöpSS) and the neuronal attention network?

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ischemic/hemmorhagic stroke
• written consent form

Exclusion criteria

• pre-existing dementia or cognitive impairment before stroke onset
• pre-existing mental disorder (depression) or present/prior long-term treatment (> 6 months) with psychotropic drugs
• pre-existing malign tumor disease
• participation in another clinical trial within the past 30 days
• pregnancy or breastfeeding

Trial design

80 participants in 1 patient group

Stroke Patients

Description:

Ischemic-/hemorragic stroke patients, who admitted on the stroke unit.

Treatment:

Diagnostic Test: Kölner Neuropsychologische Screening für Schlaganfall-Patienten